SKP.L Regulatory News (SKP)

5 Sep 2006 09:00

Skyepharma PLC05 September 2006 For Immediate Release 5 September, 2006 SkyePharma PLC SkyePharma to Announce 2006 Interim Results on 28 September LONDON, UK, 5 September 2006 - SkyePharma PLC (LSE: SKP, NASDAQ: SKYE) announcestoday that the Company will issue its interim results for the six months ended30 June 2006, to the London Stock Exchange at 07:00 a.m. BST on Thursday 28September 2006. Later that day the Company will host an analyst presentation,which will be webcast live, to be followed by a US conference call. Frank Condella, SkyePharma's Chief Executive Officer, will host the analystpresentation and the conference call. Investors and other interested parties mayview the live webcast at 10:00 a.m. BST on the Company's website atwww.skyepharma.com under the Investor Relations tab. US investors and other interested parties may access the conference call at 10:00 a.m. EDT (15:00 BST) by dialling (800) 967 7135 for US participants and +1(719) 457 2626 for international participants. The slides of the presentationwill be available on the Company's website at www.skyepharma.com under theInvestor Relations tab. For those unable to listen to the live broadcast, a replay will be availableshortly after the conference call by dialling (888) 203 1112 for US participantsand +1 (719) 457 0820 for international participants and entering Access Code1549587. For further information please contact: SkyePharma PLC +44 207 491 1777Frank Condella, Chief Executive OfficerPeter Laing, Director of Corporate Communications +44 207 491 5124Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000Tim Anderson / Mark Court / Rebecca Skye Dietrich About SkyePharma SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now twelve approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. This information is provided by RNS The company news service from the London Stock Exchange